Day: March 22, 2022

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of [Ru(p-cymene)Cl2]2 (306 mg, 0.5 mmol) and pybox-ip (301 mg, 1.0 mmol) in MeOH (7.0 mL) wasadded a solution of disodium pyridine-2,6-dicarboxylate (1.0 mmol) in MeOH-H2O (2:1 v/v, 15 mL) under argonatmosphere. The mixture was stirred at 60 oC for 1 h. The product was extracted with CH2Cl2 (40 mL). The combinedorganic layers were concentrated and the residue was purified by silica gel column chromatography withCH2Cl2MeOH (50:1 v/v) to give A* as a dark greenish-violet solid (444.0 mg, 0.78 mmol) in 78% yield.

118949-61-4, 118949-61-4 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine 688211, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Fakhruddin, Ahmad; Abu-Elfotoh, Abdel-Moneim; Shibatomi, Kazutaka; Iwasa, Seiji; Letters in Organic Chemistry; vol. 15; 3; (2018); p. 196 – 205;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.128249-70-7,2,6-Bis((R)-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine,as a common compound, the synthetic route is as follows.

Cobalt(II) tetrafluoroborate hydrate (25mg, 0.0675mmol) was added to a solution of (R)-LPh (50mg, 0.135mmol) in acetonitrile (15cm3). The resultant orange solution was stirred at room temperature for one hour. The product was precipitated using an excess of diethyl ether and the precipitate was collected by vacuum filtration, leaving an orange powder. A vapour diffusion of diethyl ether into a concentrated solution of the complex in acetonitrile gave orange crystals suitable for X-ray diffraction. Yield: 0.056g, 84%. Elemental microanalysis: found C, 56.6; H, 3.81; N, 8.53%: calcd for C46H38B2CoF8N6O4 C, 56.9; H, 3.94; N, 8.65%. 1H NMR (CD3CN): delta 2.7 (8H, Ph H2/6), 3.0 (4H, Ph H4), 7.7 (8H, Ph H3/5), 20.0 and 36.8 (both 4H, Ox H5), 40.5 (4H, Py H3/5), 84.7 (4H, Ox H4). No peak from the Py H4 proton environment was observed, which may be obscured by the CHD2CN solvent peak., 128249-70-7

The synthetic route of 128249-70-7 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.63-91-2,L-Phenylalanine,as a common compound, the synthetic route is as follows.

63-91-2, The commercially available raw materials L-phenylalanine (LOBA,99%) and D-methionine (LOBA, 99%) in the purest form were taken in an equimolar (1:1) ratio and dissolved in the double distilled water. After continuous stirring for 8 h at room temperature homogenous saturated solution was obtained which was then filtered in the vessel using whatman filter paper at room temperature. After a time span of30 days optically good quality crystals were harvested from the mother solution by solution evaporation method.

As the paragraph descriping shows that 63-91-2 is playing an increasingly important role.

Reference：
Article; Sangeetha; Jayaprakash; Nageshwari; Rathika Thaya Kumari; Sudha; Prakash; Vinitha; Lydia Caroline; Physica B: Condensed Matter; vol. 525; (2017); p. 164 – 174;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.118949-61-4,2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine,as a common compound, the synthetic route is as follows.

A 20 mL two-necked round-bottomed flask was charged with 69.2 mg (0.23 mmol, MW: 301) of pybox- ip, 87.6mg(0.46 mmol, MW: 190.45) of CuI and 5.0 mL of anhydrous CH2Cl2. A slow stream of nitrogen was passed throughthe system, and the solution was stirred well at room temperature for 24 h by means of magnetic stirring bar. Theexcess CuI was filtered off and the solvent of the filtrate was removed under reduced pressure and a yellow solid wasformed. After drying in vacuum at room temperature, the yield of F was 76.0% (85.4 mg). The structure of thiscatalyst was not confirmed., 118949-61-4

The synthetic route of 118949-61-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Fakhruddin, Ahmad; Abu-Elfotoh, Abdel-Moneim; Shibatomi, Kazutaka; Iwasa, Seiji; Letters in Organic Chemistry; vol. 15; 3; (2018); p. 196 – 205;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

128249-70-7, 2,6-Bis((R)-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Zinc(II)tetrafluoroborate hydrate (16mg, 0.068mmol) was added to a solution of (R)-LPh (50mg, 0.135mmol) in acetonitrile (15cm3). The resultant colourless solution was stirred at room temperature for one hour, before the product was precipitated using excess diethyl ether. The white precipitate was collected using vacuum filtration. Single crystals suitable for X-ray diffraction analysis were grown by vapour diffusion of diethyl ether into a concentrated solution of the product in acetonitrile. Yield: 0.056g, 84%. Elemental microanalysis: found C, 56.7; H, 3.38; N, 8.99%: calcd for C46H38B2F8N6O4Zn C, 56.5; H, 3.92; N, 8.59%. 1H NMR (CD3CN): delta 4.75 (dd, 4H, 10.8, 8,9 Hz, CH), 5.23 (dd, 4H, 10.4, 8.9Hz, ox-H), 5.15 (t, 4H, 10.6Hz, ox-H), 6.76 (d, 8H, 7.2Hz, Ph H2/6), 7.09 (t, 8H, 7.2Hz, Ph H3/5), 7.22 (m, 4H, Ph H4), 8.04 (d, 4H, 7.9Hz, Py H3/5), 8.47 (t, 2H, 7.9Hz, Py H4)., 128249-70-7

As the paragraph descriping shows that 128249-70-7 is playing an increasingly important role.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.128249-70-7,2,6-Bis((R)-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine,as a common compound, the synthetic route is as follows.

Cobalt(II) tetrafluoroborate hydrate (25mg, 0.0675mmol) was added to a solution of (R)-LPh (50mg, 0.135mmol) in acetonitrile (15cm3). The resultant orange solution was stirred at room temperature for one hour. The product was precipitated using an excess of diethyl ether and the precipitate was collected by vacuum filtration, leaving an orange powder. A vapour diffusion of diethyl ether into a concentrated solution of the complex in acetonitrile gave orange crystals suitable for X-ray diffraction. Yield: 0.056g, 84%. Elemental microanalysis: found C, 56.6; H, 3.81; N, 8.53%: calcd for C46H38B2CoF8N6O4 C, 56.9; H, 3.94; N, 8.65%. 1H NMR (CD3CN): delta 2.7 (8H, Ph H2/6), 3.0 (4H, Ph H4), 7.7 (8H, Ph H3/5), 20.0 and 36.8 (both 4H, Ox H5), 40.5 (4H, Py H3/5), 84.7 (4H, Ox H4). No peak from the Py H4 proton environment was observed, which may be obscured by the CHD2CN solvent peak., 128249-70-7

The synthetic route of 128249-70-7 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of [Ru(p-cymene)Cl2]2 (306 mg, 0.5 mmol) and pybox-ip (301 mg, 1.0 mmol) in MeOH (7.0 mL) wasadded a solution of disodium pyridine-2,6-dicarboxylate (1.0 mmol) in MeOH-H2O (2:1 v/v, 15 mL) under argonatmosphere. The mixture was stirred at 60 oC for 1 h. The product was extracted with CH2Cl2 (40 mL). The combinedorganic layers were concentrated and the residue was purified by silica gel column chromatography withCH2Cl2MeOH (50:1 v/v) to give A* as a dark greenish-violet solid (444.0 mg, 0.78 mmol) in 78% yield.

118949-61-4, 118949-61-4 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine 688211, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Fakhruddin, Ahmad; Abu-Elfotoh, Abdel-Moneim; Shibatomi, Kazutaka; Iwasa, Seiji; Letters in Organic Chemistry; vol. 15; 3; (2018); p. 196 – 205;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of [Ru(p-cymene)Cl2]2 (306 mg, 0.5 mmol) and pybox-ip (301 mg, 1.0 mmol) in MeOH (7.0 mL) wasadded a solution of disodium pyridine-2,6-dicarboxylate (1.0 mmol) in MeOH-H2O (2:1 v/v, 15 mL) under argonatmosphere. The mixture was stirred at 60 oC for 1 h. The product was extracted with CH2Cl2 (40 mL). The combinedorganic layers were concentrated and the residue was purified by silica gel column chromatography withCH2Cl2MeOH (50:1 v/v) to give A* as a dark greenish-violet solid (444.0 mg, 0.78 mmol) in 78% yield.

118949-61-4, 118949-61-4 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine 688211, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Fakhruddin, Ahmad; Abu-Elfotoh, Abdel-Moneim; Shibatomi, Kazutaka; Iwasa, Seiji; Letters in Organic Chemistry; vol. 15; 3; (2018); p. 196 – 205;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.63-91-2,L-Phenylalanine,as a common compound, the synthetic route is as follows.

63-91-2, The commercially available raw materials L-phenylalanine (LOBA,99%) and D-methionine (LOBA, 99%) in the purest form were taken in an equimolar (1:1) ratio and dissolved in the double distilled water. After continuous stirring for 8 h at room temperature homogenous saturated solution was obtained which was then filtered in the vessel using whatman filter paper at room temperature. After a time span of30 days optically good quality crystals were harvested from the mother solution by solution evaporation method.

As the paragraph descriping shows that 63-91-2 is playing an increasingly important role.

Reference：
Article; Sangeetha; Jayaprakash; Nageshwari; Rathika Thaya Kumari; Sudha; Prakash; Vinitha; Lydia Caroline; Physica B: Condensed Matter; vol. 525; (2017); p. 164 – 174;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

71071-46-0, Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

71071-46-0, General procedure: A solution of compound 5 (400mg, 0.822mmol), [(eta6-p-cymene) RuCl2]2 (252mg, 0.411mmol), and Me4NCl (450mg, 4.11mmol) in anhydrous acetone (21mL) was stirred under a dark atmosphere at room temperature for 6h. The reaction mixture was filtered and the filtrate was evaporated to afford crude compound as a bright orange solid. The above intermediate (200mg, 0.373mmol), dimethyl 2,2?-bipyridine-4,4?-dicarboxylate (203mg, 0.746mmol), and potassium hexafluorophosphate (103mg, 0.56mmol) were dissolved in dry 1,2-dichloroethane (20mL) and the mixture was stirred at 60°C for 12h. The mixture was then concentrated under reduced pressure and the resulting crude product was purified by column chromatography using ethyl acetate/ dichloromethane (1:1) to give compound 6 as a dark red solid (233mg, 70percent). 1H NMR (300MHz, CDCl3): delta 8.89 (s, 1H), 8.85 (s, 1H), 8.79 (s, 1H), 8.74 (s, 1H), 8.39 (d, J=5.7Hz, 1H), 8.00?7.91 (m, 3H), 7.82 (m, 3H), 7.67 (dd, J=3.6Hz, 1.5Hz, 1H), 7.52 (dt, J=8.7Hz, 1.2Hz, 1H), 7.46 (d, J=7.5Hz, 1H), 7.32?7.19 (m, 5H), 7.13 (d, J=5.7Hz, 1H), 6.72 (dt, J=6.5Hz, 1.5Hz, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 3.93 (s, 3H), 3.91 (s, 3H), 1.27 (s, 3H); 13C NMR (125MHz, CDCl3): delta 192.8, 164.6, 164.4, 164.2, 162.6, 157.9, 157.8, 156.5, 156.3, 155.6, 151.9, 151.4, 150.5, 149.8, 142.5, 142.4, 138.4, 137.3, 136.6, 135.6, 135.3, 135.0, 134.9, 129.4, 128.5, 127.9, 127.6, 126.3, 162.2, 125.8, 123.0, 122.9, 122.4, 120.4, 118.8, 53.6, 53.5, 53.4, 53.3, 15.5; HRMS (FAB):calcd. for C44H36N5O8RuS [M+] 896.1328, found 896.1321.

As the paragraph descriping shows that 71071-46-0 is playing an increasingly important role.

Reference：
Article; Li, Chung-Yen; Su, Chaochin; Wang, Hsiou-Hsuan; Kumaresan, Prabakaran; Hsu, Chia-Hsuan; Lee, I-Ting; Chang, Wei-Chun; Tingare, Yogesh S.; Li, Ting-Yu; Lin, Chia-Feng; Li, Wen-Ren; Dyes and Pigments; vol. 100; 1; (2014); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI